Literature DB >> 14673903

Atypical propriospinal myoclonus with possible relationship to alpha interferon therapy.

Isabelle Benatru1, Stéphane Thobois, Nathalie Andre-Obadia, Pierre-Marie Gonnaud, Yara Beaugendre, Colette Berger, Michel Gonce, Emmanuel Broussolle.   

Abstract

We report on a man who received interferon-alpha 2a therapy for kidney cancer and who subsequently developed propriospinal myoclonus. The myoclonus was noted at rest and during movement. The jerks were reinforced by cutaneous stimuli and tendon taps and spread to the spinal cord via polysynaptic propriospinal pathways. Cerebrospinal fluid analysis, spinal cord magnetic resonance imaging, electroencephalogram with back-averaging, and somatosensory-evoked potentials were normal. No antineuronal antibodies were found. Although the mechanism of interferon neurotoxicity remains unclear, the possible responsibility of interferon was considered, as no focal lesion or paraneoplastic pathology were disclosed. Copyright 2003 Movement Disorder Society

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14673903     DOI: 10.1002/mds.10614

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  2 in total

Review 1.  A novel diagnostic approach to patients with myoclonus.

Authors:  Rodi Zutt; Martje E van Egmond; Jan Willem Elting; Peter Jan van Laar; Oebele F Brouwer; Deborah A Sival; Hubertus P Kremer; Tom J de Koning; Marina A Tijssen
Journal:  Nat Rev Neurol       Date:  2015-11-10       Impact factor: 42.937

Review 2.  Propriospinal myoclonus: clinical reappraisal and review of literature.

Authors:  Sandra M A van der Salm; Roberto Erro; Carla Cordivari; Mark J Edwards; Johannes H T M Koelman; Tom van den Ende; Kailash P Bhatia; Anne-Fleur van Rootselaar; Peter Brown; Marina A J Tijssen
Journal:  Neurology       Date:  2014-10-10       Impact factor: 9.910

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.